Login to Your Account



Pharma: Other News To Note


Friday, April 5, 2013
• Noven Pharmaceuticals Inc., of Miami, said it confirmed that it filed an abbreviated new drug application seeking approval to market its rivastigmine transdermal system in 4.6 mg/24 hours and 9.5 mg/24 hours dosage strengths.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription